• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Glaukos Announces Third Quarter 2024 Financial Results

    11/4/24 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2024. Key highlights for the third quarter of 2024 include:

    • Record net sales of $96.7 million increased 24% year-over-year.
    • Glaucoma record net sales of $76.0 million increased 30% year-over-year.
    • Corneal Health net sales of $20.6 million increased 5% year-over-year.
    • Gross margin of approximately 77% and non-GAAP gross margin of approximately 82%.
    • Raised 2024 net sales guidance to $377 million to $379 million, compared to $370 million to $376 million previously.

    "Our record third quarter results reflect successful global execution of our key strategic plans and continued strong momentum in our business," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."

    Third Quarter 2024 Financial Results

    Net sales in the third quarter of 2024 of $96.7 million increased 24%, compared to $78.0 million in the same period in 2023.

    Gross margin for the third quarter of 2024 was approximately 77%, compared to approximately 76% in the same period in 2023. Non-GAAP gross margin for the third quarter of 2024 was approximately 82%, compared to approximately 83% in the same period in 2023.

    Selling, general and administrative (SG&A) expenses for the third quarter of 2024 increased 18% to $64.0 million, compared to $54.2 million in the same period in 2023. Non-GAAP SG&A expenses for the third quarter of 2024 increased 18% to $63.3 million, compared to $53.5 million in the same period in 2023.

    GAAP and non-GAAP research and development (R&D) expenses for the third quarter of 2024 increased 4% to $34.7 million, compared to $33.3 million in the same period in 2023.

    Loss from operations in the third quarter of 2024 was $24.7 million, compared to operating loss of $28.0 million in the third quarter of 2023. Non-GAAP loss from operations in the third quarter of 2024 was $18.4 million, compared to non-GAAP operating loss of $21.8 million in the third quarter of 2023.

    Net loss in the third quarter of 2024 was $21.4 million, or ($0.39) per diluted share, compared to net loss of $30.4 million, or ($0.63) per diluted share, in the third quarter of 2023. Non-GAAP net loss in the third quarter of 2024 was $15.2 million, or ($0.28) per diluted share, compared to non-GAAP net loss of $24.2 million, or ($0.50) per diluted share, in the third quarter of 2023.

    The company ended the third quarter of 2024 with approximately $267.2 million in cash and cash equivalents, short-term investments and restricted cash.

    2024 Revenue Guidance

    The company expects 2024 net sales to be in the range of $377 million to $379 million based on the latest foreign currency exchange rates.

    Webcast & Conference Call

    The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company's financial outlook. A link to the webcast is available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (international) and enter Conference ID 7935742. A replay of the webcast will be archived on the company's website following completion of the call.

    Quarterly Summary Document

    The company has posted a document on its Investor Relations website under the "Financials & Filings – Quarterly Results" section titled "Quarterly Summary." This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company's business objectives and strategies and any forward statements or guidance the company may make. This document is provided alongside the company's earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. As such, today's conference call will be in a format primarily consisting of a questions and answers session, during which Glaukos will address any queries investors have regarding the company's results. It is the company's goal that this format will make its quarterly earnings process more efficient and impactful for the investment community going forward.

    About Glaukos

    Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR therapy; the impact of general macroeconomic conditions including foreign currency fluctuations and future health crises on our business; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent, the iStent inject W, iAccess, iPRIME, iStent infinite, iDose TR, our corneal cross-linking products or other products in development, and our compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid; our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission (SEC), including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which was filed with the SEC on August 2, 2024, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which is expected to be filed with the SEC by November 12, 2024. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

    Statement Regarding Use of Non-GAAP Financial Measures

    To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) ("Non-GAAP Purposes"). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements. See "GAAP to Non-GAAP Reconciliations" for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

    In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See "Reported Sales vs. Prior Periods" for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

     
    GLAUKOS CORPORATION
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (unaudited)
    (in thousands, except per share amounts)
     
    Three Months Ended Nine Months Ended
    September 30, September 30,
     

    2024

    2023

    2024

    2023

    Net sales

    $

    96,670

     

    $

    78,048

     

    $

    277,982

     

    $

    232,346

     

    Cost of sales

     

    22,584

     

     

    18,510

     

     

    65,392

     

     

    56,684

     

    Gross profit

     

    74,086

     

     

    59,538

     

     

    212,590

     

     

    175,662

     

    Operating expenses:
    Selling, general and administrative

     

    64,000

     

     

    54,247

     

     

    192,163

     

     

    161,034

     

    Research and development

     

    34,746

     

     

    33,301

     

     

    99,898

     

     

    101,706

     

    Acquired in-process research and development

     

    -

     

     

    -

     

     

    14,229

     

     

    3,000

     

    Total operating expenses

     

    98,746

     

     

    87,548

     

     

    306,290

     

     

    265,740

     

    Loss from operations

     

    (24,660

    )

     

    (28,010

    )

     

    (93,700

    )

     

    (90,078

    )

    Non-operating income (expense):
    Interest income

     

    2,700

     

     

    2,710

     

     

    8,611

     

     

    6,252

     

    Interest expense

     

    (1,663

    )

     

    (3,398

    )

     

    (8,468

    )

     

    (10,205

    )

    Charges associated with convertible senior notes

     

    -

     

     

    -

     

     

    (18,012

    )

     

    -

     

    Other income (expense), net

     

    2,391

     

     

    (1,709

    )

     

    (338

    )

     

    (2,978

    )

    Total non-operating income (expense)

     

    3,428

     

     

    (2,397

    )

     

    (18,207

    )

     

    (6,931

    )

    Loss before taxes

     

    (21,232

    )

     

    (30,407

    )

     

    (111,907

    )

     

    (97,009

    )

    Income tax provision

     

    177

     

     

    37

     

     

    885

     

     

    873

     

    Net loss

    $

    (21,409

    )

    $

    (30,444

    )

    $

    (112,792

    )

    $

    (97,882

    )

     
    Basic and diluted net loss per share

    $

    (0.39

    )

    $

    (0.63

    )

    $

    (2.18

    )

    $

    (2.03

    )

     
    Weighted average shares used to compute basic and diluted net loss per share

     

    55,037

     

     

    48,675

     

     

    51,804

     

     

    48,284

     

     
    GLAUKOS CORPORATION
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (in thousands, except par values)
     

    September 30,

    December 31,

    2024

    2023

    (unaudited)
    Assets
    Current assets:
    Cash and cash equivalents

    $

    100,143

     

    $

    93,467

     

    Short-term investments

     

    162,330

     

     

    201,964

     

    Accounts receivable, net

     

    56,408

     

     

    39,850

     

    Inventory

     

    59,895

     

     

    41,986

     

    Prepaid expenses and other current assets

     

    18,506

     

     

    18,194

     

    Total current assets

     

    397,282

     

     

    395,461

     

    Restricted cash

     

    4,733

     

     

    5,856

     

    Property and equipment, net

     

    98,581

     

     

    103,212

     

    Operating lease right-of-use assets

     

    27,321

     

     

    27,146

     

    Finance lease right-of-use asset

     

    42,365

     

     

    44,180

     

    Intangible assets, net

     

    269,418

     

     

    282,956

     

    Goodwill

     

    66,134

     

     

    66,134

     

    Deposits and other assets

     

    20,709

     

     

    15,469

     

    Total assets

    $

    926,543

     

    $

    940,414

     

     
    Liabilities and stockholders' equity
    Current liabilities:
    Accounts payable

    $

    11,103

     

    $

    13,440

     

    Accrued liabilities

     

    60,581

     

     

    60,574

     

    Total current liabilities

     

    71,684

     

     

    74,014

     

    Convertible senior notes

     

    56,759

     

     

    282,773

     

    Operating lease liability

     

    30,656

     

     

    30,427

     

    Finance lease liability

     

    69,712

     

     

    70,538

     

    Deferred tax liability, net

     

    7,143

     

     

    7,144

     

    Other liabilities

     

    22,080

     

     

    13,752

     

    Total liabilities

     

    258,034

     

     

    478,648

     

     
    Stockholders' equity:
    Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued or outstanding

     

    -

     

     

    -

     

    Common stock, $0.001 par value; 150,000 shares authorized; 55,122 and 49,148 shares issued and 55,094 and 49,120 shares outstanding as of September 30, 2024 and December 31, 2023, respectively

     

    55

     

     

    49

     

    Additional paid-in capital

     

    1,377,825

     

     

    1,059,751

     

    Accumulated other comprehensive income

     

    2,620

     

     

    1,165

     

    Accumulated deficit

     

    (711,859

    )

     

    (599,067

    )

    Less treasury stock (28 shares as of September 30, 2024 and December 31, 2023)

     

    (132

    )

     

    (132

    )

    Total stockholders' equity

     

    668,509

     

     

    461,766

     

    Total liabilities and stockholders' equity

    $

    926,543

     

    $

    940,414

     

     
    GLAUKOS CORPORATION
    GAAP to Non-GAAP Reconciliations
    (in thousands, except per share amounts and percentage data)
    (unaudited)
     
    Q3 2024 Q3 2023
    GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP
    Cost of sales

    $

    22,584

    $

    (5,523

    )

    (a)

    $

    17,061

     

    $

    18,510

     

    $

    (5,523

    )

    (a)

    $

    12,987

     

    Gross Margin

     

    76.6%

     

    5.8%

     

    82.4%

     

    76.3%

     

    7.1%

     

    83.4%

     
    Operating expenses:
    Selling, general and administrative

    $

    64,000

     

    $

    (705

    )

    (b)

    $

    63,295

     

    $

    54,247

     

    $

    (705

    )

    (b)

    $

    53,542

     

    Loss from operations

    $

    (24,660

    )

    $

    6,228

     

    $

    (18,432

    )

    $

    (28,010

    )

    $

    6,228

     

    $

    (21,782

    )

    Net loss

    $

    (21,409

    )

    $

    6,228

     

    (c)

    $

    (15,181

    )

    $

    (30,444

    )

    $

    6,228

     

    (c)

    $

    (24,216

    )

    Basic and diluted net loss per share

    $

    (0.39

    )

    $

    0.11

     

    $

    (0.28

    )

    $

    (0.63

    )

    $

    0.13

     

    $

    (0.50

    )

    (a)

    Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $5.5 million.

    (b)

    Avedro acquisition-related amortization expense of customer relationship intangible assets of $0.7 million.

    (c)

    Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023.

     
    GLAUKOS CORPORATION
    GAAP to Non-GAAP Reconciliations
    (in thousands, except per share amounts and percentage data)
    (unaudited)
     
    Year-to-Date Q3 2024 Year-to-Date Q3 2023
    GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP
    Cost of sales

    $

    65,392

     

    $

    (16,569

    )

    (a)

    $

    48,823

     

    $

    56,684

     

    $

    (16,569

    )

    (a)

    $

    40,115

     

    Gross Margin

     

    76.5%

     

    5.9%

     

    82.4%

     

    75.6

    %

     

    7.1%

     

    82.7%

     
    Operating expenses:
    Selling, general and administrative

    $

    192,163

     

    $

    (2,115

    )

    (b)

    $

    190,048

     

    $

    161,034

     

    $

    (2,115

    )

    (b)

    $

    158,919

     

    Loss from operations

    $

    (93,700

    )

    $

    18,684

     

    $

    (75,016

    )

    $

    (90,078

    )

    $

    18,684

     

    $

    (71,394

    )

    Non-operating income (expense):
    Charges associated with convertible senior notes

    $

    (18,012

    )

    $

    18,012

     

    (c)

    $

    -

     

    $

    -

     

    $

    -

     

    $

    -

     

    Net loss

    $

    (112,792

    )

    $

    36,696

     

    (d)

    $

    (76,096

    )

    $

    (97,882

    )

    $

    18,684

     

    (d)

    $

    (79,198

    )

    Basic and diluted net loss per share

    $

    (2.18

    )

    $

    0.71

     

    $

    (1.47

    )

    $

    (2.03

    )

    $

    0.39

     

    $

    (1.64

    )

    (a)

    Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $16.6 million.

    (b)

    Avedro acquisition-related amortization expense of customer relationship intangible assets of $2.1 million.

    (c)

    Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million.

    (d)

    Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023.

     

    Reported Sales vs. Prior Periods (in thousands)
    Year-over-Year Percent Change Quarter-over-Quarter Percent Change

    3Q 2024

    3Q 2023

    2Q 2024

    Reported

    Operations (1)

    Currency (2)

    Reported

    Operations (1)

    Currency (2)

     
    International Glaucoma

    $

    24,467

    $

    20,280

    $

    26,131

    20.6%

    20.9%

    (0.2%)

    (6.4%)

    (8.2%)

    1.8%

     
    Total Net Sales

    $

    96,670

    $

    78,048

    $

    95,690

    23.9%

    23.9%

    (0.0%)

    1.0%

    0.5%

    0.5%

    (1) Operational growth excludes the effect of translational currency
    (2) Calculated by converting the current period numbers using the prior period's average foreign exchange rates

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241104442542/en/

    Get the next $GKOS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    5/6/2024$84.00 → $125.00Hold → Buy
    Jefferies
    12/21/2023$66.00 → $91.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GKOS
    SEC Filings

    See more
    • Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - GLAUKOS Corp (0001192448) (Filer)

      6/3/25 4:23:59 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Glaukos Corporation

      SD - GLAUKOS Corp (0001192448) (Filer)

      5/30/25 4:45:35 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GLAUKOS Corp (0001192448) (Filer)

      5/14/25 7:00:17 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

      Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platfor

      6/25/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

      NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on June 25th Equities are little changed Wednesday morning after jumping by more than 1% on Tuesday. The DOW gained over 500 points while the S&P 500 sits just shy of a record high.Driving those gains were easing tensions in the Middle East, resulting in crude oil prices falling by approximately 5% during Tuesday's session. President Trump announced a ceasefire agreement on Monday night.Fed

      6/25/25 8:55:00 AM ET
      $GKOS
      $ICE
      $JBS
      Medical/Dental Instruments
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we've made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye disease

      6/25/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Glaukos downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

      5/1/25 7:44:23 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos upgraded by Mizuho with a new price target

      Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously

      2/19/25 7:02:55 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos upgraded by Citigroup with a new price target

      Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously

      12/11/24 7:52:08 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      11/14/24 1:21:45 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      2/14/24 3:55:55 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      2/13/24 5:41:34 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Financials

    Live finance-specific insights

    See more
    • Glaukos Announces First Quarter 2025 Financial Results

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately

      4/30/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

      Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (Int

      4/9/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4

      2/20/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IDOSE TR issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/15/23 11:41:09 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • FDA Approval for TRAVOPROST issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/14/23 7:41:03 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hoffmeister David F exercised 25,000 shares at a strike of $32.00, increasing direct ownership by 361% to 31,918 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/13/25 7:43:41 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Director Foley Mark J was granted 2,972 shares, increasing direct ownership by 64% to 57,221 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/2/25 4:44:12 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Director Hoffmeister David F was granted 2,665 shares, increasing direct ownership by 63% to 6,918 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/2/25 4:43:25 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    See more
    • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

      1/4/23 8:00:00 AM ET
      $BLU
      $GKOS
      $INSP
      $NTLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

      Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

      12/20/21 4:15:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

      SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

      3/1/21 4:10:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care